HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of the patents listed in connection with Nuedexta® (dextromethorphan hydrobromide and quinidine sulfate 20 mg / 10 mg) capsules.
